Two Sigma Investments, LP Surface Oncology, Inc. Transaction History

Two Sigma Investments, LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$0.57 - $0.88 $5,183 - $8,001	-9,093 Reduced 19.18%	38,317 $33,000
Q1 2023 May 15, 2023	BUY	$0.61 - $1.03 $12,961 - $21,885	21,248 Added 81.22%	47,410 $33,000
Q4 2022 Feb 14, 2023	SELL	$0.62 - $1.21 $79,752 - $155,645	-128,633 Reduced 83.1%	26,162 $21,000
Q3 2022 Nov 14, 2022	SELL	$1.05 - $2.1 $25,647 - $51,294	-24,426 Reduced 13.63%	154,795 $161,000
Q2 2022 Aug 15, 2022	BUY	$1.42 - $3.15 $254,493 - $564,546	179,221 New	179,221 $294,000
Q2 2021 Aug 16, 2021	SELL	$6.45 - $9.09 $492,850 - $694,575	-76,411 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$7.25 - $13.82 $207,756 - $396,025	28,656 Added 60.01%	76,411 $596,000
Q4 2020 Feb 16, 2021	SELL	$6.87 - $10.48 $1.47 Million - $2.25 Million	-214,593 Reduced 81.8%	47,755 $441,000
Q3 2020 Nov 16, 2020	SELL	$5.06 - $7.23 $654,875 - $935,721	-129,422 Reduced 33.04%	262,348 $1.81 Million
Q2 2020 Aug 14, 2020	BUY	$1.57 - $6.56 $615,078 - $2.57 Million	391,770 New	391,770 $2.57 Million

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

Stay updated on Two Sigma Investments, LP with notifications on news.